Revolution Medicines, Inc. (RVMD) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 354.06M USD | Liabilities, Current |
| Cash and equivalents | 815.43M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 3.12B USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $354.06M | $815.43M | $3.12B | (m) | (m) | (m) |
| 2026-03-31 | (m) | $289.60M | $440.94M | $1.47B | (m) | (m) | (m) |
| 2025-12-31 | (m) | $290.42M | $383.75M | $1.64B | (m) | (m) | (m) |
| 2025-09-30 | (m) | $245.62M | $217.44M | $1.71B | (m) | (m) | (m) |
| 2025-06-30 | (m) | $184.53M | $402.44M | $1.73B | (m) | (m) | (m) |
| 2025-03-31 | (m) | $158.60M | $333.55M | $1.77B | (m) | (m) | (m) |
| 2024-12-31 | (m) | $163.91M | $543.06M | $1.75B | (m) | (m) | (m) |
| 2024-09-30 | (m) | $110.86M | $201.26M | $1.35B | (m) | (m) | (m) |
| 2024-06-30 | (m) | $105.33M | $275.71M | $1.32B | (m) | (m) | (m) |
| 2024-03-31 | (m) | $93.72M | $288.43M | $1.42B | (m) | (m) | (m) |
| 2023-12-31 | (m) | $143.85M | $696.15M | $1.16B | (m) | (m) | (m) |
| 2023-09-30 | (m) | $85.54M | $358.40M | $454.80M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $78.06M | $380.33M | $529.16M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $54.63M | $427.22M | $482.58M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $61.98M | $161.41M | $483.53M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $73.27M | $178.94M | $476.07M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $63.54M | $105.78M | $355.65M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $57.46M | $97.67M | $421.09M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $60.35M | $108.50M | $468.56M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $51.89M | $129.15M | $479.50M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $45.80M | $195.60M | $450.72M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $43.76M | $351.60M | $330.00M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $47.18M | $104.27M | $336.47M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $42.38M | $64.87M | $401.27M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $43.74M | $23.98M | $301.47M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $41.51M | $182.67M | $165.28M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $43.05M | $16.66M | $106.10M | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $21.82M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $85.47M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $62.76M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $69.59M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |